Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: A phase 2, randomised, double-blind, placebo controlled trial

Maturitas ◽

10.1016/j.maturitas.2017.03.319 ◽

2017 ◽

Vol 100 ◽

pp. 142-143

Author(s):

Julia Prague ◽

Rachel Roberts ◽

Alexander Comninos ◽

Sophie Clarke ◽

Channa Jayasena ◽

...

Keyword(s):

Controlled Trial ◽

Hot Flushes ◽

Phase 2 ◽

Double Blind ◽

Receptor Antagonism ◽

Double Blind Placebo ◽

Novel Treatment ◽

Neurokinin 3 Receptor

Download Full-text

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(17)30823-1 ◽

2017 ◽

Vol 389 (10081) ◽

pp. 1809-1820 ◽

Cited By ~ 77

Author(s):

Julia K Prague ◽

Rachel E Roberts ◽

Alexander N Comninos ◽

Sophie Clarke ◽

Channa N Jayasena ◽

...

Keyword(s):

Controlled Trial ◽

Hot Flushes ◽

Phase 2 ◽

Double Blind ◽

Receptor Antagonism ◽

Double Blind Placebo ◽

Novel Treatment ◽

Neurokinin 3 Receptor

Download Full-text

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Endocrine Abstracts ◽

10.1530/endoabs.50.oc1.1 ◽

2017 ◽

Author(s):

Julia Prague ◽

Rachel Roberts ◽

Alexander Comninos ◽

Sophie Clarke ◽

Channa Jayasena ◽

...

Keyword(s):

Controlled Trial ◽

Rapid Onset ◽

Hot Flushes ◽

Phase 2 ◽

Double Blind ◽

Receptor Antagonism ◽

Double Blind Placebo ◽

Novel Treatment ◽

Highly Effective ◽

Neurokinin 3 Receptor

Download Full-text

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

Endocrine Abstracts ◽

10.1530/endoabs.49.gp131 ◽

2017 ◽

Author(s):

Julia Prague ◽

Rachel Roberts ◽

Alexander Comninos ◽

Sophie Clarke ◽

Channa Jayasena ◽

...

Keyword(s):

Controlled Trial ◽

Hot Flushes ◽

Phase 2 ◽

Double Blind ◽

Receptor Antagonism ◽

Double Blind Placebo ◽

Novel Treatment ◽

Neurokinin 3 Receptor

Download Full-text

Faculty Opinions recommendation of Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727486566.793530603 ◽

2017 ◽

Author(s):

Robert Rebar

Keyword(s):

Controlled Trial ◽

Hot Flushes ◽

Phase 2 ◽

Double Blind ◽

Receptor Antagonism ◽

Double Blind Placebo ◽

Novel Treatment ◽

Neurokinin 3 Receptor

Download Full-text

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Case Medical Research ◽

10.31525/ct1-nct03926117 ◽

2019 ◽

Author(s):

Keyword(s):

Renal Disease ◽

Chronic Renal Disease ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.069 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P296-P296

Author(s):

Stephen H. Pasternak ◽

Carolina Silveira ◽

Zhonghan Li ◽

Robert Bartha ◽

Michael Borrie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Phase 2 ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Pharmacological Chaperone ◽

Double Blind Placebo ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial

Retrovirology ◽

10.1186/1742-4690-6-s3-o25 ◽

2009 ◽

Vol 6 (S3) ◽

Cited By ~ 1

Author(s):

D Salmon-Céron ◽

C Durier ◽

C Desaint ◽

Cuzin ◽

M Surenaud ◽

...

Keyword(s):

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Hiv 1

Download Full-text

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(19)32135-x ◽

2019 ◽

Vol 394 (10208) ◽

pp. 1540-1550 ◽

Cited By ~ 44

Author(s):

Rajiv Agarwal ◽

Patrick Rossignol ◽

Alain Romero ◽

Dahlia Garza ◽

Martha R Mayo ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Resistant Hypertension ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet Neurology ◽

10.1016/s1474-4422(11)70299-x ◽

2012 ◽

Vol 11 (2) ◽

pp. 131-139 ◽

Cited By ~ 54

Author(s):

David H Miller ◽

Thomas Weber ◽

Richard Grove ◽

Claire Wardell ◽

Joseph Horrigan ◽

...

Keyword(s):

Multiple Sclerosis ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases

10.1158/1538-7445.sabcs15-ot2-01-05 ◽

2016 ◽

Author(s):

RE Coleman ◽

L Huang ◽

O Petrenciuc ◽

P Zaccarini ◽

HS Rugo

Keyword(s):

Controlled Trial ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive ◽

Radium 223 ◽

Epidermal Growth ◽

Positive Breast Cancer

Download Full-text